UB Paderborn / Katalog / Suche / in CDI

26 – 49 von 49

Sortiert nach

Influence of Food on the Oral Bioavailability of Loratadine and Pseudoephedrine from Extended-Release Tablets in Healthy Volunteers

Journal of clinical pharmacology, 1996-10, Vol.36 (10), p.923-930

1996

Link zum Volltext

Verfügbarkeit prüfen

The Influence of Multiple-Dose Vorapaxar, an Oral PAR-1 Receptor Antagonist, on the Single-Dose Pharmacokinetics and Pharmacodynamics of Digoxin

Clinical pharmacology in drug development, 2013-01, Vol.2 (1), p.90-98

2013

Link zum Volltext

Verfügbarkeit prüfen

Interaction of Single-Dose Ezetimibe and Steady-State Cyclosporine in Renal Transplant Patients

Journal of clinical pharmacology, 2006-03, Vol.46 (3), p.328-336

2006

Link zum Volltext

Verfügbarkeit prüfen

Mometasone Furoate Has Minimal Effects on the Hypothalamic-Pituitary-Adrenal Axis When Delivered at High Doses

Chest, 2000-12, Vol.118 (6), p.1538-1546

2000

Link zum Volltext

Verfügbarkeit prüfen

Mometasone furoate nasal spray : A review of safety and systemic effects

Drug safety, 2007-01, Vol.30 (4), p.317-326

2007

Link zum Volltext

Verfügbarkeit prüfen

Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure

Clinical science (1979), 1996-09, Vol.91 (3), p.283

1996

Link zum Volltext

Verfügbarkeit prüfen

No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects

European journal of clinical pharmacology, 2012-03, Vol.68 (3), p.291-300

2012

Link zum Volltext

Verfügbarkeit prüfen

No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers

Clinical pharmacology in drug development, 2018-02, Vol.7 (2), p.143-150

2018

Link zum Volltext

Verfügbarkeit prüfen

ONCE-DAILY ADMINISTRATION OF MOMETASONE FUROATE DRY POWDER INHALER HAS NO SIGNIFICANT EFFECT ON CORTISOL CONCENTRATIONS IN SUBJECTS WITH MILD-TO-MODERATE ASTHMA

Chest, 2007-10, Vol.132 (4), p.479A-479A

2007

Link zum Volltext

Verfügbarkeit prüfen

Once-Daily Evening Dosing of Mometasone Furoate Administered via a Dry Powder Inhaler Does Not Adversely Affect the Hypothalamic-Pituitary-Adrenal Axis

Chest, 2010-01, Vol.137 (1), p.115-121

2010

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin

British journal of clinical pharmacology, 2002-09, Vol.54 (3), p.309-319

2002

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention

Circulation (New York, N.Y.), 2001-07, Vol.104 (4), p.406-411

2001

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects

European journal of clinical pharmacology, 2012-03, Vol.68 (3), p.249-258

2012

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease

European journal of clinical pharmacology, 2012-07, Vol.68 (7), p.1049-1056

2012

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation

Clinical therapeutics, 1995-03, Vol.17 (2), p.241-251

1995

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of loratadine and pseudoephedrine following single and multiple doses of once- versus twice-daily combination tablet formulations in healthy adult males

Clinical therapeutics, 1997-09, Vol.19 (5), p.1002-1012

1997

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment

European journal of clinical pharmacology, 2012-11, Vol.68 (11), p.1501-1508

2012

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects

International journal of clinical pharmacology and therapeutics, 2014-10, Vol.52 (10), p.889

2014

Link zum Volltext

Verfügbarkeit prüfen

A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study

The Journal of infectious diseases, 2022-08, Vol.226 (1), p.109-118

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial

The Journal of infectious diseases, 2019-03, Vol.219 (7), p.1026-1034

2019

Link zum Volltext

Verfügbarkeit prüfen

A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe

Clinical therapeutics, 2001-06, Vol.23 (6), p.871-885

2001

Link zum Volltext

Verfügbarkeit prüfen

Trimethoprim alters the disposition of procainamide and N‐acetylprocainamide

Clinical pharmacology and therapeutics, 1988-10, Vol.44 (4), p.467-477

1988

Link zum Volltext

Verfügbarkeit prüfen

Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide

Archives of internal medicine (1960), 1989-06, Vol.149 (6), p.1350

1989

Link zum Volltext

Verfügbarkeit prüfen

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin

European journal of clinical pharmacology, 2012-11, Vol.68 (11), p.1509-1516

2012

Link zum Volltext

Verfügbarkeit prüfen

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone

Clinical pharmacology in drug development, 2015-01, Vol.4 (1), p.56-62

2015

Link zum Volltext

Verfügbarkeit prüfen

26 – 49 von 49

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieCurrent Medical Research And Opinion

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(49)

Sprache

Englisch
(49)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Influence of Food on the Oral Bioavailability of Loratadine and Pseudoephedrine from Extended-Release Tablets in Healthy Volunteers

The Influence of Multiple-Dose Vorapaxar, an Oral PAR-1 Receptor Antagonist, on the Single-Dose Pharmacokinetics and Pharmacodynamics of Digoxin

Interaction of Single-Dose Ezetimibe and Steady-State Cyclosporine in Renal Transplant Patients

Mometasone Furoate Has Minimal Effects on the Hypothalamic-Pituitary-Adrenal Axis When Delivered at High Doses

Mometasone furoate nasal spray : A review of safety and systemic effects

Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure

No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects

No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers

ONCE-DAILY ADMINISTRATION OF MOMETASONE FUROATE DRY POWDER INHALER HAS NO SIGNIFICANT EFFECT ON CORTISOL CONCENTRATIONS IN SUBJECTS WITH MILD-TO-MODERATE ASTHMA

Once-Daily Evening Dosing of Mometasone Furoate Administered via a Dry Powder Inhaler Does Not Adversely Affect the Hypothalamic-Pituitary-Adrenal Axis

Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin

Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention

Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease

Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation

Pharmacokinetics of loratadine and pseudoephedrine following single and multiple doses of once- versus twice-daily combination tablet formulations in healthy adult males

Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment

Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects

A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study

Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial

A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe

Trimethoprim alters the disposition of procainamide and N‐acetylprocainamide

Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone

Aktive Filter

Suchergebnisse filtern